Press Release
Reproductive Freedom for All Responds to FDA Approval of New Generic Mifepristone
Washington, DC — The Food and Drug Administration (FDA) approved a new generic version of mifepristone, a medication that has been safely and effectively used in abortion care and miscarriage management for more than two decades. This approval comes amid repeated attacks from the Trump Administration on Mifepristone, and efforts to spread disinformation questioning its safety and efficacy.
Reproductive Freedom for All, President and CEO Mini Timmaraju released the following statement:
“This is exactly how our system is supposed to work, and it has worked this way for decades. Career scientists and civil servants at the FDA did their jobs—evaluating the evidence and approving a safe, effective medication. The only reason this routine approval is making headlines is because anti-abortion politicians have turned health care into a political battlefield. We miss the days when this didn’t require a comment.”
Read more about all the research behind Mifepristone’s efficacy, and the ongoing threats to Mifepristone here.
###
For over 55 years, Reproductive Freedom for All (formerly NARAL Pro-Choice America) has fought to protect and advance reproductive freedom at the federal and state levels—including access to abortion care, birth control, pregnancy and post-partum care, and paid family leave—for everybody. Reproductive Freedom for All is powered by its more than 4 million members from every state and congressional district in the country, representing the 8 in 10 Americans who support legal abortion.